Mutations in PARK2/Parkin, which encodes a ubiquitin E3 ligase, cause autosomal recessive Parkinson disease (PD). Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin's ubiquitin E3 ligase activity and protective function. c-Abl is activated by dopaminergic stress and by dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP + ) in vitro and in vivo by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), leading to parkin inactivation, accumulation of the parkin substrates aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1), and cell death. STI-571, a c-Abl-family kinase inhibitor, prevents the phosphorylation of parkin, maintaining parkin in a catalytically active and protective state. STI-571's protective effects require parkin, as shRNA knockdown of parkin prevents STI-571 protection. Conditional knockout of c-Abl in the nervous system also prevents the phosphorylation of parkin, the accumulation of its substrates, and subsequent neurotoxicity in response to MPTP intoxication. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate in the substantia nigra and striatum. Thus, tyrosine phosphorylation of parkin by c-Abl is a major posttranslational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Moreover, inhibition of c-Abl may be a neuroprotective approach in the treatment of PD.
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AIMP2 | Parkinson disease | STI-571 | ubiquitin P arkinson disease (PD) is a common neurodegenerative disorder characterized by the loss of dopamine (DA) neurons and protein accumulation in intracellular inclusions designated as Lewy bodies and Lewy neurites (1) . Although the majority of PD is sporadic in nature, rare familial mutations are providing insight into this chronic, progressive neurodegenerative disease. Mutations in α-synuclein and LRRK2 cause autosomal-dominant PD, whereas mutations in DJ-1, PINK1, and parkin result in autosomal-recessive PD (2) . Parkin mutations are the most common cause of autosomal-recessive PD and, for the most part, PD due to parkin mutations is indistinguishable from sporadic PD (3) . Parkin is a ubiquitin E3 ligase, and familial mutations are thought to impair the E3 ligase activity of parkin (4, 5) .
Parkin ubiquitinates proteins via monoubiquitination or polyubiquitination using either lysine 48 (K48) or lysine 63 (K63). Monoubiquitination by parkin is thought to regulate receptor trafficking (6) . Polyubiquitination by parkin via K48 is thought to mediate proteasomal degradation (7, 8) , whereas polyubiquitination by K63 may be involved in inclusion formation (9) . Parkin's differential ubiquitination properties are likely to be regulated by different ubiquitin-conjugating E2s and other associated proteins or regulatory processes (3) . A number of putative parkin substrates have been identified (for a review, see ref. 3) . Aminoacyl-tRNA synthetaseinteracting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1) are parkin substrates that appear to be regulated by K48 ubiquitination and proteasomal degradation because they accumulate in parkin exon 7 knockout (KO) mice and in autosomal-recessive PD brains due to parkin mutations (8) . AIMP2 may play a pathogenic role, as it is selectively toxic to DA neurons (8) . Parkin may also regulate the biologic function of other substrates (3) .
The nonreceptor tyrosine kinase c-Abl localizes to the nucleus and cytoplasm and is activated by cellular stress (10) . c-Abl plays a prominent role in tumorigenesis, as c-Abl is a homolog of the transforming element of the Abelson murine leukemia virus (11) . In brain, c-Abl is involved in neuronal plasticity, neurite outgrowth, and neurogenesis (12) . Activation of c-Abl may also play a role in neurologic disorders such as Alzheimer's disease (13) and Niemann-Pick type-2 disease (14) through aberrant activation.
Parkin's E3 ligase activity and protective function are regulated by posttranslational modifications including S-nitrosylation (15), phosphorylation (16, 17) , and dopamine conjugation (18) . Here we report functional regulation of parkin activity by phosphorylation of tyrosine 143 by c-Abl. Phosphorylation of parkin by c-Abl inhibits parkin's E3 ligase activity and protective function in both in vitro and in vivo models of PD. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate, suggesting a pathophysiologic regulation of parkin by c-Abl in sporadic PD.
Results
Parkin Interacts with c-Abl. To determine whether parkin directly interacts with c-Abl, a glutathione S-transferase (GST) pull-down assay was performed with recombinant GST-parkin and recombinant c-Abl (Fig. 1A) . c-Abl interacts with GST-parkin as determined by immunoblot with an anti-c-Abl antibody, whereas c-Abl does not interact with GST alone (Fig. 1A) . Immunoprecipitation of parkin from mouse brain coimmunoprecipitates c-Abl, indicating that c-Abl and parkin interact in vivo. c-Abl fails to coimmunoprecipitate with mouse IgG, indicating that the interaction between parkin and c-Abl is specific (Fig. 1B) . To further determine the specificity of the interaction, immunoprecipitiation was compared between wild-type (WT) and parkin KO mice. Antibodies to parkin coimmunoprecipitate c-Abl from WT brain but not parkin KO brain (Fig. S1A) . Cotransfection experiments in SH-SY5Y cells indicate that V5-tagged parkin (V5-parkin) interacts with GFP-tagged c-Abl (GFP-c-Abl) via coimmunoprecipitation of either V5 or GFP ( Fig. 1 C and D) . Interestingly, a kinase-dead (KD) (lysine 290 arginine) version of c-Abl (19) fails to interact with parkin ( Fig. 1 C and D) . To determine the domain of c-Abl that interacts with parkin, different domains of c-Abl were cotransfected with V5-parkin. Constructs of c-Abl that contain the SH3 domain interact with parkin, whereas c-Abl constructs lacking the SH3 domain fail to interact with parkin ( Fig. 1E and Fig. S1B) . Thus, the c-Abl SH3 domain is required for the interaction with parkin. To ascertain the domain of parkin that interacts with c-Abl, different myc-tagged domains of parkin were cotransfected with GFP-c-Abl. c-Abl interacts with the RING finger and in-between RING finger domains of parkin (Fig. 1F ).
c-Abl Tyrosine Phosphorylates Parkin. An in vitro kinase assay was performed using recombinant c-Abl and recombinant His 6 -tagged parkin to determine whether c-Abl is able to phosphorylate parkin. Phosphorylation was monitored with an anti-phosphotyrosine (antip-tyrosine) antibody. c-Abl tyrosine-phosphorylates parkin, and the c-Abl-family kinase inhibitor STI-571 prevents the tyrosine phosphorylation of parkin by c-Abl ( Fig. 2A) . To determine the site of phosphorylation of parkin by c-Abl, two-dimensional (2-DE) gel electrophoresis was used to separate phosphorylated from nonphosphorylated parkin (Fig. 2B) . c-Abl-phosphorylated parkin was submitted for mass spectrometry for determination of the phosphorylation site. Mass spectrometric analysis provided 96.5% sequence coverage of parkin, and all tyrosine residues were investigated for phosphorylation status. Only tyrosine 143 is phosphorylated, whereas none of the other tyrosines are phosphorylated (Fig. 2B) . To confirm that tyrosine 143 was the sole site of phosphorylation by c-Abl, tyrosine 143 in parkin was mutated to phenylalanine to create a Y143F parkin mutant. Cotransfection experiments in SH-SY5Y cells indicate that WT parkin is phosphorylated by c-Abl but not c-Abl-KD. c-Abl is not able to tyrosine-phosphorylate parkin Y143F (Fig. 2C) . These results taken together indicate that c-Abl phosphorylates parkin on tyrosine 143.
Tyrosine Phosphorylation of Parkin Inhibits Its Ubiquitin E3 Ligase Activity. To determine whether c-Abl phosphorylation of parkin modulates parkin's ubiquitination activity, autoubiquitination of parkin was monitored in the presence of kinase-active c-Abl (c-Abl-KA) or c-Abl-KD. SH-SY5Y cells were cotransfected with V5-tagged parkin and HA-tagged ubiquitin followed by immunoprecipitation of parkin. Parkin is autoubiquitinated, as detected by anti-HA immunoreactivity as previously reported (Fig. 3A ) (4, 5) . Kinase-active c-Abl, which tyrosine-phosphorylates parkin, almost completely inhibits the autoubiquitination of parkin, whereas c-Abl-KD has no effect (Fig. 3A) . To ascertain whether tyrosine 143 is required for the c-Abl-mediated inhibition of parkin autoubiquitination, WT parkin and Y143F parkin autoubiquitination were monitored in the presence of c-Abl-KA or c-Abl-KD. WT parkin ubiquitination is inhibited by c-Abl-KA, whereas it has no effect on parkin Y143F ubiquitination (Fig. 3B) . c-Abl-KD has no effect on WT parkin or Y143F parkin autoubiquitination (Fig. 3B) . Next, the effects of c-Abl on parkin ubiquitination of AIMP2 were monitored. Parkin ubiquitinates AIMP2 as previously described (8, 20) and Y143F parkin also ubiquitinates AIMP2 (Fig. 3C ). c-Abl-KA impairs WT parkin ubiquitination of AIMP2, but c-Abl-KD has no effect (Fig. 3C) . Y143F parkin ubiquitination of AIMP2 is not affected by either c-Abl-KA or c-Abl-KD (Fig. 3C) . To pharmacologically confirm the role of c-Abl in tyrosine-phosphorylating parkin and inhibiting its ubiquitination function, AIMP2 ubiquitination by parkin was evaluated in the presence and absence of STI-571, a c-Abl-family kinase inhibitor. The c-Abl-mediated tyrosine phosphorylation of parkin and the inhibition of parkin's ubiquitination of AIMP2 are prevented by STI-571 (Fig. 3D) . To determine whether c-Abl affects parkin's ubiquitination of other substrates, the ubiquitination of FBP1 was monitored. FBP1 ubiquitination by parkin is inhibited by c-Abl-KA, and STI-571 inhibits the c-Abl-mediated tyrosine phosphorylation of parkin and restores the ubiquitination of FBP1 (Fig. S2) .
Dopaminergic Stress Activates c-Abl Inhibiting Parkin's E3 Ligase
Activity and Protective Function. Different types of genotoxic stress are known to activate c-Abl (21) . To determine whether PD-associated stressors activate c-Abl, we monitored c-Abl activation with an anti-p-tyrosine antibody to tyrosine 245 of c-Abl in SH-SY5Y cells transfected with V5-parkin. The DA neurotoxin 1-methyl-4-phenylpyridinium (MPP + ) (250 μM) or DA (250 μM) activates c-Abl, as determined by the anti-p-tyrosine 245 c-Abl antibody (Fig. 4A ). c-Abl activation by MPP + or DA is attenuated by the c-Abl-family kinase inhibitor STI-571 (Fig. 4A) . Accompanying the activation of c-Abl by MPP + or DA is tyrosine phosphorylation of parkin, as detected with an anti-p-tyrosine antibody against immunoprecipitated parkin. The tyrosine phosphorylation of parkin is completely attenuated by STI-571 (Fig.  4A) or suppression of c-Abl expression with siRNA (Fig. S3A) . MPP + or DA also increases the level of the parkin substrate AIMP2, and this increase is blocked by STI-571 (Fig. 4A) or suppression of c-Abl expression with siRNA (Fig. S3A) . To determine whether activation of c-Abl by MPP + or DA impairs parkin's ubiquitination activity, parkin autoubiquitination was monitored in SH-SY5Y cells transfected with V5-parkin. Both MPP + and DA reduce parkin autoubiquitination, which is attenuated by STI-571 (Fig. 4B) or knockdown of c-Abl expression with siRNA (Fig. S3B) .
The susceptibility of PC-12 cells to AIMP2-induced cell death was used to determine whether tyrosine phosphorylation of parkin by c-Abl regulates parkin's protective function. A Tet-offinducible PC-12 cell line that overexpresses AIMP2 in the absence of doxycycline was developed to monitor AIMP2 toxicity (Fig.  S3C ). In the absence of doxycycline, AIMP2 is substantially induced, leading to a greater than twofold increase in cell death as monitored by trypan blue exclusion (Fig. 4C) . In noninduced cells, MPP + treatment leads to a greater than threefold increase in cell death that is significantly inhibited by STI-571 (Fig. 4C ). AIMP2 toxicity is unaffected by STI-571, and STI-571 treatment alone has no substantial effect on cell viability in noninduced cells (Fig. 4C) . MPP + treatment enhances AIMP2 toxicity, and this enhancement is inhibited by STI-571 (Fig. 4C) . Parkin overexpression attenuates AIMP2 toxicity, but MPP + treatment prevents parkin's protective effects against AIMP2 toxicity. Coadministration of STI-571 restores parkin's protective effects against AIMP2 toxicity in the setting of MPP + treatment (Fig. 4C ). Y143F parkin protects against AIMP2 toxicity and MPP + treatment is incapable of attenuating Y143F parkin's protective properties. Similar results were observed with DA stress-induced toxicity (Fig. S3D) . These results taken together indicate that parkin's protective function is impaired by the PD-associated stressors MPP + and DA through c-Abl-mediated phosphorylation of parkin at tyrosine 143.
To determine whether the protective effects of STI-571 require parkin, shRNA was used to knock down parkin and the ability of STI-571 to protect against MPP + toxicity was monitored. shRNA to GFP was used as a control. Knockdown of parkin leads to an upregulation of AIMP2 (Fig. 4D) . MPP + treatment leads to tyrosine phosphorylation of c-Abl and parkin, which further increases AIMP2 levels. STI-571, which prevents the tyrosine phosphorylation of parkin by c-Abl, attenuates the increase in AIMP2 levels. In the setting of parkin knockdown, c-Abl inhibition by STI-571 has no effect on AIMP2 levels (Fig. 4D) . MPP + treatment of SH-SY5Y cells leads to a twofold increase in toxicity as assessed by trypan blue exclusion, which is prevented by STI-571 (Fig. 4E) or suppression of c-Abl expression with siRNA (Fig. S3E) . Parkin knockdown attenuates the ability of STI-571 (Fig. 4E) or knockdown of c-Abl (Fig. S3E ) to protect against MPP + toxicity. Taken together, these results indicate that STI-571 protective effects require parkin. (Fig. 5A ). There is a twofold increase in tyrosine phosphorylation of parkin, a threefold increase in AIMP2, and a moderate increase in FBP1 that accompanies the activation of c-Abl. In c-Abl KO mice, c-Abl is not detectable, as expected (Fig. 5A) . Following MPTP intoxication, there is no increase in tyrosine phosphorylation of parkin and no increase in AIMP2 and FBP1 levels ( + (250 μM) for 24 h. Some samples were incubated with 10 μM STI-571. Cell lysates were subjected to immunoprecipitation with an anti-parkin antibody. The parkin immunoprecipitates were immunoblotted with anti-phosphotyrosine to monitor tyrosine phosphorylation of parkin and anti-parkin to monitor the levels of immunoprecipitated parkin. Total lysates were immunoblotted with anti-phospho-cAbl to show tyrosine-phosphorylated c-Abl, anti-actin as a loading control, and with an AIMP2 antibody to monitor the levels of AIMP2 and an anti-parkin antibody to confirm the parkin knockdown by parkin-shRNA. Data were repeated with similar results. (E) Trypan blue cell death assessments in SH-SY5Y neuroblastoma cells that were transiently transfected with parkin-shRNA or GFP-shRNA and treated with MPP + (200 μM). Some samples were incubated with 10 μM STI-571 as indicated. Data are mean ± SEM for three separate experiments performed in duplicate. Statistical significance was determined by one-way ANOVA and Tukey's post hoc test. ***P < 0.001.
significantly prevents the loss of TH-positive and Nissl-positive neurons following MPTP intoxication (Fig. 5 C and D) . Equivalent levels of MPP + , the active metabolite of MPTP, are observed in WT and c-Abl KO animals, indicating that the protective effect observed in c-Abl KO mice is not due to altered bioavailability of MPP + (Fig. 5E ). Striatal TH-positive fiber density was assessed in WT and c-Abl KO mice after MPTP administration. MPTP leads to a 50% reduction in TH-positive fiber density in the striatum of WT mice. KO of c-Abl significantly protects against the loss of striatal TH-positive fibers (Fig. S5 A and B) . Taken together, these data indicate that c-Abl activation plays a role in DA cell loss following MPTP intoxication.
Activation of c-Abl in Sporadic PD. The potential pathophysiologic relevance of c-Abl activation and tyrosine phosphorylation of parkin was monitored in human postmortem brain tissue from PD patients and age-matched controls (Tables S1 and S2 ). Cell lysates were prepared from substantia nigra, striatum, and cortex. In substantia nigra and striatum from PD patient samples, there is a significant increase in tyrosine-phosphorylated c-Abl over agematched control tissue (Fig. 6 A and B) . There is also a significant increase in tyrosine-phosphorylated parkin and a significant increase in AIMP2 and FBP1 levels in PD substantia nigra and striatum. There is a strong positive correlation between phosphorylated c-Abl and phosphorylated parkin and between phosphorylated parkin and levels of AIMP2 and FBP1 in substantia nigra and striatum (Fig. S6) . There is no significant difference between the levels of tyrosine-phosphorylated c-Abl, tyrosinephosphorylated parkin, AIMP2, or FBP1 in cortex, a region relatively unaffected in PD (Fig. 6C) . To determine whether other c-Abl substrates are tyrosine-phosphorylated in PD, tyrosine phosphorylation of cyclin-dependent kinase 5 (CDK5), a wellknown c-Abl kinase substrate, was monitored (25) . There is a significant increase in tyrosine-phosphorylated CDK5 in PD substantia nigra and striatum compared with controls (Fig. S7) . Taken together, these results indicate that c-Abl activation and tyrosine phosphorylation of parkin and the accumulation of the parkin substrates AIMP2 and FBP1 occur in PD and appear to be specific to the nigrostriatal system.
Discussion
The major finding of this study is that c-Abl is a major regulator of parkin function. c-Abl phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity, leading to accumulation of AIMP2 and FBP1 and loss of parkin's . Parkin is tyrosine-phosphorylated in the striatum and substantia nigra of PD patients. Anti-parkin IP samples from substantia nigra (A), striatum (B), and cortex lysates (C) were immunoblotted with anti-phosphotyrosine antibodies to monitor tyrosine-phosphorylated parkin, anti-parkin antibodies to show immunoprecipitated parkin, anti-c-Abl antibodies to show coimmunoprecipitated c-Abl, and anti-ubiquitin to show ubiquitinated parkin. Brain lysates were immunoblotted with anti-AIMP2, anti-phospho-c-Abl, anti-c-Abl, and anti-FBP1 antibodies to monitor their levels and an anti-actin antibody was used as a loading control. Relative phospho-parkin levels normalized to immunoprecipitated parkin, relative phospho-c-Abl levels normalized to c-Abl, and relative AIMP2 and FBP1 levels normalized to β-actin are indicated in D (substantia nigra), E (striatum), and F (cortex). The data are the mean ± SEM. Statistical significance was determined by applying the unpaired two-tailed Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001. All experiments were repeated at least three times and representative images of the immunoblots are shown.
cytoprotective function and cell death. The c-Abl-family kinase inhibitor STI-571 maintains parkin in a catalytically active and neuroprotective state by preventing the tyrosine phosphorylation of parkin. shRNA knockdown of parkin attenuates STI-571 protection, indicating that the protective effect of STI-571 is parkindependent. c-Abl is active in sporadic PD substantia nigra and striatum, correlating with the increase in phosphorylated parkin and accumulation of AIMP2 and FBP1. These data implicate c-Abl as an important regulator of parkin's E3 ligase activity and cytoprotective function and identify c-Abl as a potentially important therapeutic target for the treatment of PD. Our findings provide further support to the idea that parkin is inactivated in sporadic PD. Previous studies suggest that parkin is inactivated in sporadic PD through S-nitrosylation (15, 26), oxidative stress (27) , and dopamine conjugation (18). Here we describe another posttranslational modification of parkin that is present in sporadic PD. Thus, parkin inactivation is emerging as a common event in sporadic PD. Maintaining parkin function through inhibition of S-nitrosylation, dopamine conjugation, or phosphorylation by c-Abl is an attractive therapeutic target. Parkin inactivation by c-Abl may be a dominant pathway, because inhibition of c-Abl with STI-571 or knockdown and knockout of c-Abl prevents the inactivation of parkin by MPTP and DA.
The mechanisms underlying c-Abl activation in sporadic PD await further characterization. One of the possible mechanisms, however, can be partially explained by oxidative stress, which is prevalent in sporadic PD brain, because various oxidative stressors activate c-Abl (28). In addition, as shown here, dopaminergic stress also increases c-Abl activity. In sporadic PD, c-Abl activation and parkin inactivation and accumulation of parkin substrates appear to be limited to the striatum and substantia nigra, regions of the brain that are primarily affected in PD, as these changes are not observed in the cerebral cortex of PD patients. Thus, activation of c-Abl, tyrosine phosphorylation of parkin, and accumulation of parkin substrates may contribute to the pathogenesis of sporadic PD.
c-Abl inhibitors are widely used in the treatment of chronic myeloid leukemia. Because the c-Abl inhibitor maintains parkin in a catalytically active neuroprotective state and KO of c-Abl protects against dopaminergic cell loss following MPTP intoxication, the testing and use of brain-permeable c-Abl inhibitors as a neuroprotective treatment for PD are reasonable and potentially exciting objectives.
Materials and Methods
All methods used in this article are routinely used in our laboratories and are thus referenced (7, 8, 24, 29) and are described in SI Materials and Methods. For protein interactions, standard coimmunoprecipitation experiments and ubiquitination assays were used as previously described (7, 8) . For LC-MS/MS, excised 2-DE spots were subjected to a modified in-gel trypsin digestion procedure. Protein identity was determined by the software program Sequest (Thermo Finnigan). Conditional c-Abl knockouts were used, and MPTP intoxication studies and assessments in mice were performed as previously described (24, 29) . 
ACKNOWLEDGMENTS. This work was supported by NIH/NINDS Grants

Supporting Information
Ko et al. 10 .1073/pnas.1006083107 SI Materials and Methods Plasmids, Antibodies, and Reagents. Plasmids. The full-length and truncated mutants for human parkin (ΔUBL, R1-IBR, and R2) were cloned into pRK5-myc vector (Stratagene). Ubiquitin was cloned into pRK5-HA vector (Stratagene). Full-length human FBP1 was kindly provided by David Levens (National Cancer Institute, National Institutes of Health, Bethesda, MD). FLAGtagged aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) has been described previously (1) . GFP-cAbl-KA (kinase-active) and GFP-c-Abl-KD (kinase-dead) were kindly provided by Dr. Z.M. Yuan (Harvard School of Public Health, Boston, MA). Plasmids for c-Abl wild-type and c-Abl deletion mutants (F1-F3) were kindly provided by Dr. Baojie Li (Institute of Molecular and Cell Biology, Singapore). c-Abl deletion mutants (F4-F5) were cloned into pCMV-Tag2A-FLAG vector (Stratagene). GST-parkin was cloned into pGEX-4T-1 (Amersham Biosciences). V5-tagged parkin and V5-tagged Y143F parkin constructs were provided by Dr. S.Z. Imam (University of Texas Health Science Center, San Antonio, TX). A plasmid containing β-galactosidase, empty vector, or GFP cDNA was used as a control in the cell-culture experiments. GST pull-down assay. GST fusion proteins were prepared following a standard protocol. For in vitro binding assays, parkin GST fusion proteins bound to the glutathione sepharose beads were incubated with c-Abl recombinant proteins. After washing, the bound proteins were separated by SDS/PAGE and immunoblotted with indicated antibodies. Coimmunoprecipitation and immunoblot analysis. For coimmunoprecipitation from cell cultures, SH-SY5Y cells were transiently transfected with indicated plasmids. After 48 h, cells were washed with cold PBS and harvested in immunoprecipitation buffer (1% Triton X-100, 2 μg/mL aprotinin, and 100 μg/mL PMSF in PBS). The lysate was then rotated at 4°C for 1 h, followed by centrifugation at 14,000 rpm for 20 min. The supernatants were then combined with 40 mL of protein-G Sepharose (Amersham Biosciences) preincubated with indicated antibodies, followed by rotating for 2 h or overnight at 4°C. The protein-G Sepharose was pelleted and washed three times using immunoprecipitation buffer or buffer with additional 500 mM NaCl, followed by three washes with PBS. The precipitates were resolved on SDS/PAGE and subjected to immunoblot analysis. Immunoblot signals were visualized with chemiluminescence (Pierce). The tissues including human brain regions from striatum, substantia nigra, and cortex and mouse brain were homogenized in lysis buffer [10 mM Tris·HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 10 mM Na-β-glycerophosphate, Phosphate Inhibitor Mixture I and II (Sigma), and Complete Protease Inhibitor Mixture (Roche), using a Diax 900 homogenizer (Sigma). After homogenization, samples were rotated at 4°C for 30 min for complete lysis, the homogenate was centrifuged at 52,000 rpm for 20 min, and the resulting fractions were collected. Protein levels were quantified using the BCA Kit (Pierce) with BSA standards and analyzed by immunoblot. The supernatant was used for immunoprecipitation with either of the following antibodies: mouse IgG (mlgG) or anti-parkin. The immunocomplexes were then washed with immunoprecipitation buffer six times and separated by SDS/PAGE and subjected to immunoblot analysis with indicated antibodies. Immunoblot signals were visualized with chemiluminescence. shRNA-parkin constructs and siRNA-c-Abl. MISSION short-hairpin RNA (shRNA) plasmids (Sigma) encoding small interfering RNAs (siRNAs) targeting parkin were purchased from Sigma. Two plasmids (#1: TRCN0000000281 and #3: TRCN0000000285) were effective in knocking down parkin expression. siRNA targeting c-Abl (S864 and S866) and scrambled control siRNA were purchased from Applied Biosystems. 2D gel electrophoresis and immunoblot. Recombinant His 6 -tagged parkin or phosphorylated His 6 -parkin by c-Abl was followed by 2D gel electrophoresis (2-DE) immunoblotting. Each sample was suspended in 1.5 mL of sample buffer consisting of 40 mM Tris, 7 M urea (Sigma), 2 M thiourea (Sigma), 4% CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propane-sulfonate) (Sigma), 65 mM DTT (Bio-Rad Laboratories), 1 mM EDTA, protease inhibitors mixture (Roche), and 1 mM phenylmethylsulfonyl chloride. The suspension was concentrated and desalted by a centrifugal filter (Millipore) at 3,500 rpm for 3 h. Samples were applied on immobilized pH 4-7 nonlinear gradient strips (13 cm). Focusing started at 200 V and the voltage was gradually increased to 8,000 V at 3 V/min (≈151,000 Vh). After the first dimension, strips were equilibrated for 15 min in the equilibration buffer containing 6 M urea, 20% glycerol, 2% SDS, and 2% DTT and then for 15 min in the same equilibration buffer containing 2.5% iodoacetamide instead of DTT. After equilibration, strips were loaded on 9-16% gradient SDS gels for second-dimensional separation. The gels (180 × 200 × 1.5 mm) were run at 40 mA per gel. Immediately after the second-dimension run, gels were transferred to PVDF membrane and anti-His or anti-phosphotyrosine antibody was applied for 2-DE immunoblotting. The corresponding phosphospot in Coomassie-stained 2-DE gel was used for identification of the phosphorylation site via MS/MS. Phosphorylation analysis by LC-MS/MS. Excised 2-DE spots were subjected to a modified in-gel trypsin digestion procedure (2) . Gel pieces were washed and dehydrated with acetonitrile for 10 min followed by removal of acetonitrile. Pieces were then completely dried in a speed vac. Rehydration of the gel pieces was accomplished with 50 mM ammonium bicarbonate solution containing 12.5 ng/μL modified sequencing-grade trypsin (Promega) at 4°C. Samples were then placed in a 37°C room overnight. Peptides were later extracted by removing the ammonium bicarbonate solution, followed by one wash with a solution containing 50% acetonitrile and 1% formic acid. The extracts were then dried in a speed vac (∼1 h). The samples were then stored at 4°C until analysis. The samples were reconstituted in 5 mL of HPLC solvent A (2.5% acetonitrile, 0.1% formic acid). A nanoscale reversephase HPLC capillary column was created by packing 5-mm C18 spherical silica beads into a fused silica capillary (100-mm inner diameter × ∼12-cm length) with a flame-drawn tip (3). After equilibrating the column, each sample was pressure-loaded offline onto the column. The column was then reattached to the HPLC system. A gradient was formed and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid). As each peptide was eluted, it was subjected to electrospray ionization and then entered into an LTQ-Orbitrap mass spectrometer (Thermo Finnigan). Eluting peptides were detected, isolated, and fragmented to produce a tandem mass spectrum of specific fragment ions for each peptide. Peptide sequences (and hence protein identity) were determined by matching protein or translated nucleotide databases with the acquired fragmentation pattern by the software program Sequest (Thermo Finnigan) (4). The modification of 79.9663 mass units to serine, threonine, and tyrosine was included in the database searches to determine phosphopeptides. Each phosphopeptide that was determined by the Sequest program was also manually inspected to ensure confidence. In vitro phosphorylation assays. For in vitro kinase assays, 2.5 μg His 6 -parkin recombinant protein was incubated with 250 ng c-Abl recombinant protein, unless otherwise indicated, in a kinase buffer (20 mM Hepes, pH 7.4, 10 mM MgCl 2 , 5 mM EGTA, 150 mM NaCl, 20 mM β-glycerol phosphate) for 45 min at 30°C. STI-571 was used at concentrations as indicated in the figure legends. Phosphorylated proteins were separated by SDS/PAGE or 2D gel electrophoresis (2-DE) and analyzed by immunoblot or by LC-MS/MS. Ubiquitination assay. SH-SY5Y cells were transiently transfected with various plasmid combinations as indicated. Forty-eight hours later the cells were lysed in 2% SDS buffer [2% SDS, 150 mM NaCl, 10 mM Tris·HCl, pH 8.0, 1% Phosphatase Inhibitor Mixtures I and II (Sigma), protease inhibitors] and boiled for 10 min followed by sonication. Lysates were diluted 1:10 in dilution buffer (10 mM Tris·HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100) and incubated at 4°C for 1 h with rotation. The samples were split for use as input and for immunoprecipitation. Immunoprecipitated proteins were washed with washing buffer (10 mM Tris·HCl, pH 8.0, 500 mM NaCl, 1 mM EDTA, 1% Nonidet P-40), boiled in SDS sample buffer, and separated on SDS/PAGE. Immunoblot analysis experiments were performed using standard procedures. Detection was performed with Super Signal West Pico and Femto chemiluminescent substrates (Pierce Biotechnology). , and the offspring were bred to homozygosity at the loxP-flanked c-Abl locus. This enabled the Cre recombinase to inactivate the c-Abl gene specifically in cells in which the Nestin promoter is active (i.e., neuronal cells). The presence of the floxed c-Abl gene was determined by PCR around the 3′ loxP site using the primer (primer-2) 5′-TGT GCA TAG CAG GAA GTC CTC CAG AG-3′ and (primer-3) 5′-AGT TAA CAC ACC TCC AGA GTG AGT GCC CT-3′, yielding a PCR product of ∼200 bp for WT and a product of ∼239 bp for the floxed allele. Cre-mediated excision of c-Abl genomic sequences was detected by PCR on DNA isolated from tail snips of mice using the forward primer (primer-1) 5′-GAT GTC TCT ACA GGG TTA AG A TTA AGA GCA-3′ and the reverse primer (primer-3) 5′-AGT TAA CAC ACC TCC AGA GTG AGT GCC CT-3′, giving no band for nonrecombined allele and a product of ∼300 for recombined floxed allele, resulting in the deletion of c-Abl gene as described previously (5) . PCR to detect the presence of Nestin-Cre allele was performed using Cre primers, Cre forward primer 5′-GGA AGG TGT CCA ATT TAC TGA CCG TA-3′, and Cre reverse primer 5′-AAA TGT TGC TGG ATA GTT TTT ACT GC-3′ yielding a product of ∼200 bp. AIMP2-inducible cell lines. PC12 cells were grown in DMEM containing 10% horse serum, 5% Tet-approved FBS in a 5% CO 2 atmosphere. To create Tet-off PC12 cell lines inducibly expressing AIMP2, PC12 Tet-off cells containing pTet-off were purchased from Clontech. PC12 Tet-off cells (Clontech) were used to create PC12 cell lines expressing inducible AIMP2. A Tet-responsive AIMP2 expression construct was engineered by cloning the full-length cDNA of AIMP2 into pTRE (Clontech) vector. The AIMP2 construct was cotransfected into PC12 Tetoff cells with pTK-Hyg (Clontech) at a 10:1 molar ratio. Single colonies were obtained by limiting dilution of cells cultured in the presence of 100 μg/mL G418, 200 μg/mL hygromycin B (Clontech), and 200 ng/mL Dox for 2-3 wk. Clones were analyzed for the expression of AIMP2 by immunoblotting. Differentiation was initiated by the addition of 100 ng/mL NGF to the culture medium (DMEM with N2 supplement). NGF was replenished every day after differentiation. Cell culture, transfections, and siRNA experiments. Human neuroblastoma SH-SY5Y cells were cultured as described previously (1) and AIMP2-inducible Tet-off PC12 cell lines were maintained in DMEM supplemented with 10% horse serum, 5% Tet-approved FBS, and the following antibiotics: 100 U/mL penicillin/streptomycin (Invitrogen), 100 μg/mL G418 (Invitrogen), and 200 μg/ mL hygromycin (Invitrogen). After cryoprotection in 20% and 30% sucrose/PBS (pH 7.4), brains were frozen and serial coronal sections (30-μm sections) were cut with a microtome. Free-floating 30-μm sections were blocked with 4% goat serum/PBS plus 0.2% Triton X-100 and incubated with antibody against tyrosine hydroxylase (rabbit polyclonal; Novus Biologicals) followed by incubation with biotin-conjugated antirabbit antibody (goat polyclonal; Jackson ImmunoResearch), ABC reagents (Vector Laboratories), and SigmaFast DAB Peroxidase Substrate (Sigma-Aldrich). Sections were counterstained with Nissl (0.09% thionin). TH-positive or Nissl-positive cells from the substantia nigra pars compacta region of the left hemisphere were counted by using an optical fractionator, an unbiased method for cell counting. This method was carried out by using a computer-assisted image analysis system consisting of an Axiophot photomicroscope (Carl Zeiss Vision) equipped with a computercontrolled motorized stage (Ludl Electronics), a Hitachi HV C20 video camera, and Stereo Investigator software (MicroBrightField). The total number of TH-and Nissl-stained neurons was calculated by using the formula previously described for this method (7) . For densitometry analysis of the fiber density in the striatum stained with an anti-TH antibody, the data were analyzed by using optical density measurement tools in ImageJ software (National Institutes of Health). The mean density of striatal regions from each group of mice was normalized by the intensity of the region outside of the striatum; the normalized intensities were compared for each group.
Statistical Analysis. Pooled results were expressed as means ± SEM. Statistical significance was determined by one-way ANOVA and Tukey's post hoc test or a two-tailed nonpaired Student's t test unless otherwise noted in the figure legend. Significance was set at P ≤ 0.05. Quantitative analysis of TH-immunoreactive fibers using optical density measurement tools in ImageJ software in the striatum. The data are the mean ± SEM (n = 6). Statistical significance was determined by one-way ANOVA and Tukey's post hoc test. *P < 0.05, ***P < 0.001. . Correlation between phosphorylated c-Abl and phosphorylated parkin and between phosphorylated parkin and levels of AIMP2 and FBP1 in substantia nigra and striatum of Parkinson disease (PD) brains. There is a strong positive correlation between phosphorylated c-Abl and phosphorylated parkin in substantia nigra (R 2 = 0.8327, P < 0.0005) (A) and striatum (R 2 = 0.4808, P < 0.005) (B) and between phosphorylated parkin and AIMP2 in substantia nigra (R 2 = 0.5414, P < 0.05) (C) and striatum (R 2 = 0.63, P < 0.0005) (D) and between phosphorylated parkin and FBP1 in substantia nigra (R 2 = 7656, P < 0.001) (E) and striatum (R 2 = 0.5285, P < 0.005) (F). . CDK5 is tyrosine-phosphorylated in the striatum and substantia nigra of PD patients. Brain lysates from substantia nigra (A) and striatum (C) were immunoblotted with anti-phospho-CDK5 antibody to monitor tyrosine-phosphorylated CDK5 on tyrosine 15. Relative phospho-CDK5 levels normalized to CDK5 are indicated in B (substantia nigra) and D (striatum). The data are the mean ± SEM. Statistical significance was determined by applying the unpaired two-tailed Student's t test. *P < 0.05. Table S2 . Human postmortem tissues used for immunoblots in Fig. 6 B and 
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